Top

Langenbeck's Archives of Surgery

Published in:

01-11-2016 | ORIGINAL ARTICLE

Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery

Authors: Thilo Welsch, Benjamin Müssle, Marius Distler, Holger Knoth, Jürgen Weitz, Dennis Häckl

Published in: Langenbeck's Archives of Surgery | Issue 7/2016

Abstract

Purpose

Postoperative pancreatic fistula (POPF) is a major determinant of pancreatic surgery outcome, and prevention of POPF is a relevant clinical challenge. The aim of the present study is to compare the cost-effectiveness of octreotide and pasireotide for POPF prophylaxis.

Methods

A systematic literature review and meta-analysis and a retrospective patient cohort provided the data. Cost-effectiveness was calculated by the incremental cost-effectiveness ratio (ICER) and by decision tree modelling of hospital stay duration.

Results

Six randomised trials on octreotide (1255 patients) and one trial on pasireotide (300 patients) were included. The median POPF incidence without prophylaxis was 19.6 %. The relative risks for POPF after octreotide or pasireotide prophylaxis were 0.54 or 0.45. Octreotide prophylaxis (21 × 0.1 mg) costs were 249.69 Euro, compared with 728.84 Euro for pasireotide (14 × 0.9 mg) resulting in an ICER of 266.19 Euro for an additional 1.8 % risk reduction with pasireotide. Decision tree modelling revealed no significant reduction of median hospital stay duration if pasireotide was used instead of octreotide.

Conclusion

Prophylactic octreotide is almost as effective as pasireotide but incurs significantly fewer drug costs per case. However, the data quality is limited, because the effect of octreotide on clinically relevant POPF is unclear. Together with the lack of multicentric data on pasireotide and its effectiveness, a current off-label use of pasireotide does not appear to be justified.

Available only for authorised users

Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319CrossRefPubMed

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1210, discussion 1210–1CrossRefPubMed

Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A et al (2007) Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 142:20–25CrossRefPubMed

Yekebas EF, Wolfram L, Cataldegirmen G, Habermann CR, Bogoevski D et al (2007) Postpancreatectomy hemorrhage: diagnosis and treatment: an analysis in 1669 consecutive pancreatic resections. Ann Surg 246:269–280CrossRefPubMedPubMedCentral

Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13CrossRefPubMed

Harnoss JC, Ulrich AB, Harnoss JM, Diener MK, Büchler MW, Welsch T (2014) Use and results of consensus definitions in pancreatic surgery: a systematic review. Surgery 155:47–57CrossRefPubMed

Malleo G, Pulvirenti A, Marchegiani G, Butturini G, Salvia R, Bassi C (2014) Diagnosis and management of postoperative pancreatic fistula. Langenbeck’s Arch Surg 399:801–810CrossRef

Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM (2007) Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 245:443–451CrossRefPubMedPubMedCentral

Denbo JW, Orr WS, Zarzaur BL, Behrman SW (2012) Toward defining grade C pancreatic fistula following pancreaticoduodenectomy: incidence, risk factors, management and outcome. HPB (Oxford) 14:589–593CrossRef

10.

Gurusamy KS, Koti R, Fusai G, Davidson BR (2013) Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev 4, CD008370

11.

Haane C, Mardin WA, Schmitz B, Dhayat S, Hummel R et al (2013) Pancreatoduodenectomy—current status of surgical and perioperative techniques in Germany. Langenbeck’s Arch Surg 398:1097–1105CrossRef

12.

Allen PJ, Gönen M, Brennan MF, Bucknor AA, Robinson LM et al (2014) Pasireotide for postoperative pancreatic fistula. N Engl J Med 370:2014–2022CrossRefPubMed

13.

Gurusamy KS, Gluud C, Nikolova D, Davidson BR (2009) Assessment of risk of bias in randomized clinical trials in surgery. Br J Surg 96:342–349CrossRefPubMed

14.

Alghamdi AA, Jawas AM, Hart RS (2007) Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Can J Surg 50:459–466PubMedPubMedCentral

15.

Koti RS, Gurusamy KS, Fusai G, Davidson BR (2010) Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford) 12:155–165CrossRef

16.

Li-Ling J, Irving M (2001) Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 88:190–199CrossRefPubMed

17.

Zeng Q, Zhang Q, Han S, Yu Z, Zheng M et al (2008) Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas 36:18–25CrossRefPubMed

18.

Büchler M, Friess H, Klempa I, Hermanek P, Sulkowski U et al (1992) Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 163:125–130, discussion 130–1CrossRefPubMed

19.

Fernández-Cruz L, Jiménez Chavarría E, Taurà P, Closa D, Boado MA, Ferrer J (2013) Prospective randomized trial of the effect of octreotide on pancreatic juice output after pancreaticoduodenectomy in relation to histological diagnosis, duct size and leakage. HPB (Oxford) 15:392–399CrossRef

20.

Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B et al (1995) Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg 82:1270–1273CrossRefPubMed

21.

Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E et al (1995) Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 117:26–31CrossRefPubMed

22.

Pederzoli P, Bassi C, Falconi M, Camboni MG (1994) Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg 81:265–269CrossRefPubMed

23.

Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM et al (2004) Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. Arch Surg 139:288–294, discussion 295CrossRefPubMed

24.

Keck T, Wellner UF, Bahra M, Klein F, Sick O et al (2015) Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): perioperative and long-term results of a multicenter randomized controlled trial. Ann Surg 263:440–449CrossRef

25.

Gudjonsson B (1995) Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg 181:483–503PubMed

26.

Ljungman D, Lundholm K, Hyltander A (2011) Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure. World J Surg 35:662–670CrossRefPubMed

27.

Morris S, Gurusamy KS, Sheringham J, Davidson BR (2015) Cost-effectiveness of preoperative biliary drainage for obstructive jaundice in pancreatic and periampullary cancer. J Surg Res 193:202–209CrossRefPubMedPubMedCentral

28.

Morris S, Gurusamy KS, Sheringham J, Davidson BR (2015) Cost-effectiveness of diagnostic laparoscopy for assessing resectability in pancreatic and periampullary cancer. BMC Gastroenterol 15:44CrossRefPubMedPubMedCentral

29.

Rosenberg L, MacNeil P, Turcotte L (1999) Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. J Gastrointest Surg 3:225–232CrossRefPubMed

30.

Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ et al (1997) Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 226:632–641CrossRefPubMedPubMedCentral

31.

Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J et al (2000) Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 232:419–429CrossRefPubMedPubMedCentral

32.

Daskalaki D, Butturini G, Molinari E, Crippa S, Pederzoli P, Bassi C (2011) A grading system can predict clinical and economic outcomes of pancreatic fistula after pancreaticoduodenectomy: results in 755 consecutive patients. Langenbeck’s Arch Surg 396:91–98CrossRef

33.

Abbott DE, Sutton JM, Jernigan PL, Chang A, Frye P et al (2016) Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes. J Surg Oncol in press

34.

Belyaev O, Herzog T, Chromik AM, Meurer K, Uhl W (2013) Early and late postoperative changes in the quality of life after pancreatic surgery. Langenbeck’s Arch Surg 398:547–555CrossRef

Title: Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery
Authors: Thilo Welsch
Benjamin Müssle
Marius Distler
Holger Knoth
Jürgen Weitz
Dennis Häckl
Publication date: 01-11-2016
Publisher: Springer Berlin Heidelberg
Published in: Langenbeck's Archives of Surgery / Issue 7/2016
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-016-1456-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2016

Joint Meeting of the German Association of Endocrine Surgeons (CAEK) and the British Association of Endocrine and Thyroid Surgeons (BAETS)

The CaPTHUS score as predictor of multiglandular primary hyperparathyroidism in a European population

The viewpoint-specific failure of modern 3D displays in laparoscopic surgery

Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism

Extralaryngeal branching of the recurrent laryngeal nerve: a meta-analysis of 28,387 nerves

Perioperative application of somatostatin analogs for pancreatic surgery—current status in Germany